Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Aclaris Therapeutics Inc shares valued at $256,357 were purchased by Leonard Braden Michael on Aug 05 ’24. At $1.24 per share, Leonard Braden Michael acquired 206,025 shares. The insider’s holdings grew to 14,250,000 shares worth approximately $25.65 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Leonard Braden Michael purchased 167,544 shares, netting a total of over 216,400 in proceeds. Following the buying of shares at $1.29 each, the insider now holds 14,043,975 shares.
Before that, Leonard Braden Michael had added 173,730 shares to its account. In a trade valued at $226,370, the 10% Owner bought Aclaris Therapeutics Inc shares for $1.30 each. Upon closing the transaction, the insider’s holdings increased to 173,730 shares, worth approximately $24.8 million.
As published in a research note from H.C. Wainwright on January 22, 2024, Aclaris Therapeutics Inc [ACRS] has been rated down from a Buy to a Neutral. Analysts at William Blair downgraded the stock from ‘”an Outperform”‘ to ‘”a Mkt perform”‘ outlook in a report released in mid November. As of October 03, 2023, Evercore ISI has initiated its “an Outperform” rating for ACRS. Earlier on December 14, 2022, Stifel initiated its rating. Their recommendation was “a Buy” for ACRS stock.
Analyzing ACRS Stock Performance
During the last five days, there has been a surge of approximately 42.86%. Over the course of the year, Aclaris Therapeutics Inc shares have jumped approximately 71.43%. Shares of the company reached a 52-week high of $1.8700 on 10/29/24 and a 52-week low of $0.8555 on 01/12/24. A 50-day SMA is recorded $1.2262, while a 200-day SMA reached $1.2135. Nevertheless, trading volume fell to 0.74 million shares from 1.73 million shares the previous day.
Support And Resistance Levels for Aclaris Therapeutics Inc (ACRS)
According to the 24-hour chart, there is a support level at 1.6883, which, if violated, would cause prices to drop to 1.5767. In the upper region, resistance lies at 1.8733. The next price resistance is at 1.9467. RSI (Relative Strength Index) is 81.75 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.3552, which suggests the price will decrease in the coming days. Percent R is at 9.72%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
